200 related articles for article (PubMed ID: 17117177)
1. The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression.
Ferru A; Fromont G; Gibelin H; Guilhot J; Savagner F; Tourani JM; Kraimps JL; Larsen CJ; Karayan-Tapon L
Br J Cancer; 2006 Dec; 95(12):1670-7. PubMed ID: 17117177
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma.
Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM
Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959
[TBL] [Abstract][Full Text] [Related]
3. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer.
Pallante P; Federico A; Berlingieri MT; Bianco M; Ferraro A; Forzati F; Iaccarino A; Russo M; Pierantoni GM; Leone V; Sacchetti S; Troncone G; Santoro M; Fusco A
Cancer Res; 2008 Aug; 68(16):6770-8. PubMed ID: 18701502
[TBL] [Abstract][Full Text] [Related]
4. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
5. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
6. Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland.
Weber A; Langhanki L; Schütz A; Wittekind C; Bootz F; Tannapfel A
J Pathol; 2002 Nov; 198(3):326-34. PubMed ID: 12375265
[TBL] [Abstract][Full Text] [Related]
7. Expression of TAp73 and DeltaNp73 isoform transcripts in thyroid tumours.
Ferru A; Denis S; Guilhot J; Gibelin H; Tourani JM; Kraimps JL; Larsen CJ; Karayan-Tapon L
Eur J Surg Oncol; 2006 Mar; 32(2):228-30. PubMed ID: 16290057
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction.
Egawa C; Miyoshi Y; Iwao K; Shiba E; Noguchi S
Oncology; 2001; 61(4):293-8. PubMed ID: 11721176
[TBL] [Abstract][Full Text] [Related]
9. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
[TBL] [Abstract][Full Text] [Related]
10. Effects of CDKN2A (p16INK4A/p14ARF) Over-Expression on Proliferation and Migration of Human Melanoma A375 Cells.
Bai M; Yu NZ; Long F; Feng C; Wang XJ
Cell Physiol Biochem; 2016; 40(6):1367-1376. PubMed ID: 27997910
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
12. Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours.
Marques AR; Espadinha C; Frias MJ; Roque L; Catarino AL; Sobrinho LG; Leite V
Br J Cancer; 2004 Aug; 91(4):732-8. PubMed ID: 15238980
[TBL] [Abstract][Full Text] [Related]
13. Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers?
Letsas KP; Vartholomatos G; Tsepi C; Tsatsoulis A; Frangou-Lazaridis M
Neoplasma; 2007; 54(1):57-62. PubMed ID: 17203893
[TBL] [Abstract][Full Text] [Related]
14. PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues.
Lacroix L; Mian C; Barrier T; Talbot M; Caillou B; Schlumberger M; Bidart JM
Eur J Endocrinol; 2004 Sep; 151(3):367-74. PubMed ID: 15362967
[TBL] [Abstract][Full Text] [Related]
15. Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers.
Pacifico A; Goldberg LH; Peris K; Chimenti S; Leone G; Ananthaswamy HN
Br J Dermatol; 2008 Feb; 158(2):291-7. PubMed ID: 18070208
[TBL] [Abstract][Full Text] [Related]
16. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer.
Lee M; Sup Han W; Kyoung Kim O; Hee Sung S; Sun Cho M; Lee SN; Koo H
Pathol Res Pract; 2006; 202(6):415-24. PubMed ID: 16675157
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between alterations of p16INK4a and p14ARF genes of CDKN2A locus and gastric carcinogenesis].
Tang SH; Yang DH; Luo HS; Yu JP; Shu JC
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):517-21. PubMed ID: 15231134
[TBL] [Abstract][Full Text] [Related]
19. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.
Bièche I; Ruffet E; Zweibaum A; Vildé F; Lidereau R; Franc B
Thyroid; 1997 Oct; 7(5):725-31. PubMed ID: 9349575
[TBL] [Abstract][Full Text] [Related]
20. Fibrillin expression and localization in various types of carcinomas of the thyroid gland.
Tseleni-Balafouta S; Gakiopoulou H; Fanourakis G; Voutsinas G; Litsiou H; Sozopoulos E; Balafoutas D; Patsouris E
Mod Pathol; 2006 May; 19(5):695-700. PubMed ID: 16528372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]